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Abstract 
In response to glucose, co-ordinated and timely secretion of glucagon 
and insulin from the pancreatic islets underlie the physiological regulation of 
carbohydrate metabolism. The interplay of multiple endocrine, neurocrine 
and paracine factors results in the precise regulation of secretion of the islet 
hormones. Neuropeptide Y QSlPY), a 36 amino acid peptide, is an abundant 
neuropeptide in the central nervous system and is present in nerve terminals 
innervating the islets. Local gene expression and peptide production o f N P Y 
have been reported in islet cells. Previous studies have demonstrated that 
NPY inhibits insulin but stimulates glucagon secretion from the islets. 
However, the mechanism implicated in these observations remains unclear. 
The present study therefore investigated the actions of NPY on glucagon gene 
expression and cytosolic calcium level using a glucagon-producing hamster islet 
A cell line (MUG9). 
Synthetic NPY (final concentrations from l O ] � to 10_6 M) was added 
to the incubation medium 2, 4，8 andl6 hours before isolation of total RNA, 
which was anaylzed by Northern blot analysis. In these cells, NPY increased 
proglucagon mRNA level in the presence of high glucose concentration (11 
mM) but not in low glucose (5mM). The elevation of proglucagon gene 
expression was dose-dependent from 10"^ ^ to 10'^  M of NPY and was 
detected after 16 hours of treatment but not earlier. In contrast, no effect of 
iii 
NPY was detected on proinsulin gene expression in another insulin-producing 
cell line fRin 1056A). 
To further investigate the effect of NPY on the InRlG9 cells, the 
cellular calcium dynamics were monitored by using confocal laser scanning 
microscopy. Jn the presence of 11 mM glucose, 50 - 60% of the InRlG9 cells 
studied exhibited spontaneous Ca�+ oscillation of varying frequency, 
amplitude and regularity. Upon challenge with 10'^ M NPY, the frequency 
and amplitude of Ca�+ oscillation were elevated in both spontaneously 
oscillating and non-oscillating cells. Elevation of cytosolic Ca�+ is a 
prerequisite for Ca^^-regulated exocytosis and thus it is conceivable that NPY 
promotes exocytosis via the Ca�+ signaling system. The NPY-stimulated Ca�+ 
increase was markedly reduced by removal of external Ca�+ but not 
significantly affected by 5 ^iM nifedipine, suggesting that NPY may cause 
Ca2+ influx and this influx is probably via a pathway other than L-type 
channels. Likewise, pretreatment of 0.1 ^lM thapsigargin also reduced the 
NPY effect substantially, suggesting an involvement of Ca�+ release from 
internal stores as well. 
Taken together, our findings suggest that NPY acts on glucagon-
producing islet cell line to increase proglucagon gene expression and 
intracellular Ca�+ concentration. Hence, the previously reported NPY effect 
on glucagon secretion may be due to a concomitant increase in biosynthesis 
and exocytosis of glucagon. 
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1.1 Pancreas and Islets of Langerhans 
The pancreas is a secretory organ located behind the stomach. It 
secrets both metabolic hormones and digestive enzymes, and serves vital 
endocrine and exocrine functions. The endocrine pancreatic function is 
ascribed to the various distinctive cell types within the islets of 
Langerhans, which scatter throughout the exocrine pancreas and contribute 
to about 1 to 2% of adult pancreatic mass. 
The anatomy of the islets of Langerhans has been well established 
(for review, see Weir and Bonner-Weir, 1990; Bonner-Weir, 1991). The 
islets are composed of four major endocrine cell types, namely the 
giucagon-producing A cells, insulin-producing B cells, somatostatin-
producing D cells and pancreatic polypeptide-producing PP cells. 
Majority of the B cells occupy the central core of the islets, whilst the A, 
D and PP cells are at the periphery ^Figure 1.1). The islets are highly 
vascularized with direct arteriolar blood supply. Previous studies have 
demonstrated that the microvascular blood flows through the B cells before 
nourishing A cells and D cells (Samols et al., 1988). Furthermore, the 
islets are richly innervated by autonomic nerve fibers, 
tomunohistochemical studies have suggested that these fibers may contain 
various neuropeptides such as neuropeptide Y, galanin, vasoactive 
intestinal polypeptide, substance P and calcitonin gene-related peptide 
(Sundler and Bottcher, 1991 for review). 
1 
(a ) f — ~ ~ ~ ~ ~ ~ ~ 
• ' - ¾ 
‘ ,,.'> ^if' 
拿 、 _ ^ ‘ • 
' , ’ > . , 1 t , 4 ^ 
^ ' t � CWH:; ., , * ' J ' 
• fe>=、,％p,A�:/ / ‘ 工 
. 、 〜 ， v : : . # _ ' — ' v 
: ， 、 “ • ， • • � 
^ ' - _ 8 ' ' 二 , ， * , ； \t,^^} J ‘^ � 
( b ) | « f r « « ® ^ » ? « f ^ 7 ™ ® ~ ™ ® ® ® ~ ? f " ? ® * ~ ® 
,', " f . >� i^^ “ \ 身 :i' “ \ ) '~, j " , , ‘ " ” 吻 ‘ ^ ‘ 广 V , 、 ‘ / _ ^ , , �� 
‘ 、 斧 、 . , \ � K , , ; \ / , � ‘ 
， V : 、 " ’ （ 。 「 ， 
' : • V ^ ^ ^ ^ \ ' \ ^ “ ‘ > 
考,:¾ 
海 i ‘： 




Figure 1.1 Histology of pancreatic islets, (a) glucagon-producing A 
cells are stained; Qy) insulin-producing B cells are stained. 
(Courtesy ofDr. Y. C. Lee) 
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1.1.1 Islet Hormones and Glucose Balance 
The two major islet hormones, namely glucagon and insulin, are 
central to the maintenance of glucose balance. For example, when plasma 
glucose level drops below the mean concentration, which is around 5.5 
mM, secretion of glucagon from A cells is stimulated. The function of 
glucagon is to promote mobilization of glucose and the principal site of 
action is the liver, in which glucagon stimulates glycogenolysis and 
glugoneogenesis. On the contrary, insulin is released from B cells during 
hyperglycemia. Insulin, on the one hand, activates the glucose transporter 
system to promote cellular uptake of glucose by muscle and adipose cells 
from the circulation; on the other hand, it stimulates glycolysis and 
glycogenesis in these tissues, and in the liver as well. 
Deficiency or abnormal secretion of these hormones results in 
disturbances of the glucose homeostasis, leading to serious health 
problems. For instance, excess glucagon secretion in the face of insulin 
deficiency or resistance have been implicated in diabetes mellitus (for 
reviews, see Lefebvre, 1991 and Pfeifer and Broadstone, 1991). Likewise, 
severe hypoglycemia may cause lethargy, coma, convulsions and even 
death (Gerich et al., 1991 for review). Therefore, the maintenance of a 
glucose balance is of immense importance and the timely and coordinated 
secretions of glucagon and insulin are necessary. 
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1.1.2 Glucagon and Its Derived Peptides 
Glucagon is a 29 amino acid peptide derived from the precursor 
protein, proglucagon. The gene encoding proglucagon also contains the 
sequences of two glucagon-like peptides in tandem ^Lund et al., 1982; Bell 
et al., 1983). The gene is expressed primarily in the A cells of the 
pancreatic islets and the L cells of the small intestine (Holst and 0rskov, 
1994). In addition, it has been demonstrated that the proglucagon gene is 
also expressed in brainstem and hypothalamus ^Drucker and Asa, 1988a; 
Lee et al., 1990; Lui et al., 1990). 
A. Tissue-specific Post-translational Processing 
Upon post-translational processing, it leads to the production of a 
group of peptide hormones, collectively known as proglucagon-derived 
peptides, with different physiological functions (Conlon, 1988 for review). 
However, this process is tissue-specific. In the pancreatic A cells, 
proglucagon is processed to yield the glicentin-related pancreatic peptide 
(GRPP), glucagon and the major proglucagon fragment (MPGF) as 
depicted in Figure 1.2. (Mojsov et al, 1986; Holst et al, 1994a). The 
physiological function of glucagon is well established but the roles of 
GRPP and MPGF are not clear. Moreover, about 15 - 20 % of the MPGF 
may further be processed to yield the glucagon-like peptide-1 (GLP-1), 
intervening peptide-2 (ff-2) and glucagon-like peptide-2 (GLP-2) (Holst 
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Figure 1.2 Post-translation processing of proglucagon in pancreas and 
intestine resulting in different profiles of peptide products. 
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and 0rskov, 1994b; Holst et al., 1994c). 
In the intestine, the processing of proglucagon is different from that 
in the pancreas, resulting in a different profile of proglucagon-derived 
peptides ^lgure 1.2). The products include glicentin, GLP-1, JP-2 and 
GLP-2 (George et al., 1985; Fehmann et al., 1995). Glicentin may further 
be processed to GRPP and oxyntomodulin. Both of them are 
physiologically active and are capable of potently inhibiting gastric acid 
secretion (Bataille, 1989; Conlon, 1988; Schjoldager et aI., 1988), whereas 
the roles of IP-2 and GLP-2 remain unclear. Full-length GLP-1 is 
biologically inactive; however, after truncation of a hexapeptide at its 
amino-terminus, it is the most potent insulinotropic peptide isolated so 
far. It is always referred to as truncated GLP-1 or GLP-l(7-36) amide. 
The amidated form of truncated GLP-1 is believed to be the natural 
occurring product (Kreymann et al., 1987; Holst et al.，1987; Holst, 1994a) 
but other studies have suggested that the non-amidated GLP-l(7-37) is an 
equally potent insulin secretagogue (Weir et al.，1989; Mojsov et al., 
1990). Li brainstem and hypothalamus, the post-translational processing 
of proglucagon has not been elucidated. 
B. Features of Proglucagon Gene 
The mammalian proglucagon gene spans about 10 kilobase pairs 
containing six exons and five introns, and transcription of the gene is 
6 
directed by the TATA box OBell et al., 1983; Heinrich et al., 1984; White 
and Saunders, 1986). 
Control of gene transcription is extremely complicated and the 
contemporary understanding of the subject has recently been reviewed by 
Tjian (1995; Figure 1.3). In simplified terms, transcription is initiated 
upon the binding of RNA polymerase to the core promoter, for which 
basal transcription factors are required. Furthermore, this process can be 
up- or down-regulated by interaction of the ^ra/25-acting elements, such as 
the activators and repressors, with the enhancer and silencer sequences 
respectively. These sequences are also known as the cw-acting elements, 
which can be located either upstream or downstream of the gene. With 
this sophisticated machinery, the initiation and rate of transcription can 
therefore be precisely regulated. 
The features of the glucagon gene transcription unit have been 
extensively studied. For instance, the tissue specific expression of 
glucagon in pancreas (Drucker et al., 1987a), intestine Q^ee et al., 1992) and 
brain ^Lee et al., 1993) is determined by the cw-acting elements located 
within the 2 kilobases of the 5'-flanking region of the gene. More recent 
findings have located within 300 basepairs several upstream elements, 
including the G1, G2, G3 and G4 elements, which confine glucagon gene 
expression to the A cells of pancreatic islets (Philippe et al, 1988; Morel et 
al., 1995; Cordier-Bussat et al., 1995) respectively. In addition, the 
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Figure 1.3 The moiecular apparatus controlling gene transcription. To 
tum on transcription，RNA polymerase binds to the core 
proraoter with the aid ofbasal factors and activators {trans-
acting elements) which binds to the enhancer sequences 
(cj5-elements). Repressor binds to the silencer to down-
reguIate the process. (From Tjian, Scientific American, 
February 1995) 
8 
presence of a cAMP-responsive element (CRE) together with the CRE 
binding proteins (Knepel et al., 1990; Miller et al., 1993) further supports 
the previous findings that glucagon gene is regulated by a cAMP-
dependent pathway (Drucker and Brubaker, 1989) as well as a protein 
kinase A-dependent pathway (Drucker et al., 1991). Moreover, glucagon 
gene transcription was found to be negatively regulated by insulin through 
the interaction of the insulin-responsive G3 element and two islet-specific 
protein complexes (Philippe, 1995). And this direct action of insulin on 
glucagon expression is supported by the demonstration of functional 
insulin receptors on clonal pancreatic alpha cells ^"ehmann et al., 1994; 
Kisanuki et al., 1995). Besides, a glucocorticoid-responsive element has 
been reported (Wang et al., 1991), whereas proglucagon-derived peptides 
is found to inhibit the expression of its own gene ^Drucker et al., 1992). 
Taken together, fine regulation of the expression of proglucagon can be 
achieved by multiple pathways, and therefore, the highly coordinated 
production of glucagon is ascertained. 
1.1.3 Insulin and Features of Its Gene 
Lisulin is a polypeptide containing two peptide chains which are 
connected by two disulfide bonds. The A chain is 21 amino acid long 
while the B chain has 30 amino acids. The two chains, in conjunction with 
a31 amino acid long connecting-peptide (C-peptide), are synthesized as a 
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single-chain polypeptide (Figure 1.4). The gene encoding proinsulin is 
specifically expressed in the B cells of pancreatic islets. Post-translational 
processing and modification of proinsulin result in the liberation of the C-
peptide and production of the dimer structure of mature insulin (for 
review，see Espinal, 1989). 
The insulin gene shares high sequence similarities across species, of 
which the human gene spans 1500 base pairs and consists of three exons 
and two introns (for review, see Philippe, 1991). Consensus sequences of 
the TATA box as well as the CAAT box have been found in the insulin 
gene promoter. Tissue specific expression of insulin is conferred by the 
c/>elements, El , E2 and E3 (Cordier-Bussat et al., 1995). The trans-
elements such as insulin enhancer binding factor-1 (ffiF-l), insulin 
promoter factor-1 (PF-1) and somatostatin trans-activating factor-1 (STF-
1) also contribute to the B cell specificity (Ohlsson et al., 1988; Serup et 
al., 1995). Besides, it has been well-documented that glucose is a key 
regulator of insulin secretion and gene expression. A glucose-sensitive 
element has recently been located in the rat insulin I gene (Melloul and 
Cerasi, 1994). In fact, the same study has also suggested the presence of a 
trans-2iQXing glucose-sensitive factor for the gene. Similar to glucagon, 
expression of insulin is also mediated by a cAMP-dependent pathway 
(Drucker et al., 1987b) and a functional CRE on the insulin gene has been 
identified (Philippe and Missotten, 1990). 
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Figure 1.4 Diagramatic representation of the primary structure of 
proinsulin. Post-translational processing results in the 
liberation ofC-peptide and dimer structure ofinsulin. 
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1.2 Regulation of Islet Hormone Secretion 
The primary regulator of pancreatic secretions of glucagon and 
insulin is circulating glucose. Secretion of glucagon is suppressed by 
glucose (Sumida et al., 1994), while on the contrary, secretion of insulin is 
potentiated (Hampton et al., 1986). In addition, regulation of islet 
hormone secretion is under the influences of factors of endocrine, paracrine 
and neuroendocrine origins. An endocrine factor is originated from distant 
endocrine gland and transported via bloodstream, whereas a 
neuroendocrine factor is of neural origin and transmitted by neurons. 
Paracrine factor is released into the interstitial fluid, targeting cells of near 
proximity. 
1.2.1 Endocrine Control 
The observation that oral ingestion rather than intravenous 
injection ofglucose is a more effective stimulant of insulin release leads to 
a proposed regulatory system known as the enteroinsular axis (for 
reviews, seeEnsinck and D'Alessio, 1992; Habener, 1993; Brown, 1994). 
This axis describes the influence of hormones from the gastrointestinal 
tract on the secretion of islet hormones, which leads to the "incretin" 
concept. An incretin is a gut-derived insulinotropic substance which is 
released in response to oral glucose load. There are two incretin hormones 
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identified to date, which are the glucose-dependent insulinotropic peptide 
(GH>) and the truncated glucagon-like peptide-1 [GLP-l(7-36)amide]. 
A. Gff 
Qjp is a duodenal endocrine peptide released from the crypt cells 
and was the first incretin hormone isolated. It is also known as gastric 
inhibitory peptide because of its inhibitory action on gastric acid release. 
The physiological functions of GJP have been extensively studied and it is 
found that GJP is released postprandially to stimulate the secretion of 
insulin from pancreatic B cells (for review, see Pederson, 1994). With 
respect to the effect on glucagon release, a differential action of GEP on 
different species has been reported. But recent results have suggested that 
GJP may regulate secretion of intestinal proglucagon-derived peptides 
including truncated GLP-1 ^loberge and Brubaker, 1993). However, GIP 
alone cannot account for the full incretin effect and the truncated GLP-1 
has later been identified to act synergistically with GEP to achieve the full 
incretin action OFehmann et al., 1989; Nauck et al., 1993). 
B. Truncated GLP-1 
Truncated GLP-1 or GLP-l(7-36)amide, the intestinal product of 
proglucagon-derived peptides, is produced by the endocrine L cells in the 
distal ileum. It qualifies as a physiological incretin as it is originated from 
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intestine and is released in response to oral ingestion of food (Holst, 
1994a; Fehmann et al., 1992; Habener, 1993). At elevated glucose level, 
GLP-l(7-36)amide is a potent insulin and somatostatin secretagogue in the 
pancreas (0rskov et al., 1988; D'Alessio et al., 1989a; Kawai et al., 1989)， 
and this insulinotropic effect of the peptide is even more potent than GIP 
(Shima et al., 1988). Furthermore, inhibition of glucagon release by GLP-
l(7-36)amide has also been reported in the pancreas (0rskov et al., 1988; 
Suzuki et al., 1989; Komatsu et al., 1989). The action of GLP-l(7-
36)amide is glucose-sensitive (Zawalich et al., 1993; Holz et al., 1993) and 
the insulinotropic action is diminished when the glucose level drops below 
5 mM (Habener, 1993). Taken together, GLP-l(7-36)amide has been 
suggested as a potential therapeutic agent for treatment of non-insulin-
dependent diabetes mellitus because of its dual insulinotropic and 
glucagonostatic properties (Gutniak et al., 1992; Thorens and Waeber, 
1993; Amiel, 1994). 
1.2.2 Paracrine Control 
Intra-islet interaction has been proposed to be an important 
pathway ofregulation of release of glucagon and insulin ( for reviews, see 
Samols et al., 1986; Marks et al., 1992). For instance, secretion of 
glucagon from A cells is suppressed by insulin while that ofinsulin from B 
cells is potentiated by glucagon. Somatostatin is found to be inhibitory to 
14 
both glucagon and insulin release (Taborsky J r , 1983; D'Alessio et al., 
1989b). The influence of insulin on glucagon and somatostatin release is 
probably via the microvasculature and thus is an endocrine route. 
However, as the blood flows from B cells to A cells and D cells, it is 
unlikely that the hormones secreted from the latter cell types reach the B 
cells via the bloodstream. The architecture of the islets of Langerhans 
allows a close contact of different cell types. Therefore the peptide 
hormones may be secreted to the interstitial fluid, diffuse and act on 
neighboring cells. Actions of glucagon and somatostatin on insulin release 
are possibly via this paracrine route. There is also an autocrine mode of 
communication, in which hormones secreted from a cell may modify the 
activities of its own origin. 
In addition to glucagon, insulin and somatostatin, there are other 
peptides colocalized in the islets. For instance, pancreastatin (Bretherton-
Watt et al., 1988) and amylin (Ohsawa et al., 1989) are expressed in the 
islets and have been found to have inhibitory effects on glucose-stimulated 
insulin secretion. Neuropeptide Y OSTPY) is another islet peptide which 
may be involved in the regulation of endocrine pancreatic secretions. 
1.2.3 Neuroendocrine Control 
The islets are richly innervated by autonomic nerve fibers, which 
contain various neurotransmitters and neuropeptides (Sundler and 
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Bottcher, 1991). Galanin is one of the examples, of which actions on islet 
hormone secretions have been reported. Galanin is a 29 amino acid 
peptide with widespread distribution in the central nervous system (for 
review, see R6kaeus, 1994). Earlier reports suggested that galanin 
suppressed secretion of insulin and somatostatin at normal or elevated 
glucose, but inhibition of glucagon release was observed only at low 
glucose (Hermansen, 1988). Li a recent study using a mouse islet system, 
galanin was found to be a potent inhibitor of insulin secretion stimulated 
by glucose. However, proinsulin biosynthesis was only moderately 
inhibited while proinsulin mRNA level was not afFected, leading to a 
suggestion that galanin may be a modulator of insulin secretion by 
inhibiting the release of secretory granules ^.indskog et al., 1995). 
Calcitonin-gene related peptide is another neuropeptide present in islet 
innervation, which was found to be inhibitory to insulin secretion but 
stimulatory to glucagon secretion (Ohsawa et al., 1989; Pettersson et al., 
1987). Neuropeptide Y, another intrapancreatic neuropeptide, also affects 
islet secretions. 
1.3 Neuropeptide Y 
Neuropeptide Y QSfPY) is a 36 amino acid peptide first isolated in 
porcine brain by Tatemoto and his colleagues (1982). Together with 
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pancreatic polypeptide (PP) and peptide YY (PYY), it belongs to the PP 
family in which they are both structurally and biologically similar. 
1.3.1 NPY in Central Nervous System 
NPY is widely distributed in the central nervous system. In 
mammalian brain, it is the most abundant neuropeptide although the 
regional distribution may differ in different species (Adrian et al., 1983; 
Allen et al., 1983), and NPY immunoreactivity has also been reported in 
spinal cord (Allen et al, 1984). Since its discovery, NPY has been 
extensively studied. In central nervous system, it is the most powerful 
stimulant offood intake (for review, see Stanley, 1993). Besides, it exerts 
widespread effects on multiple physiological and behavioral processes 
such as relieving anxiety, modulating cognitive process and stimulating 
luteinizing hormone release, as discussed in several reviews (Wettstein et 
aL, 1995; Leibowitz, 1994; White, 1993). NPY is also a widespread 
neuropeptide in the autonomic nervous system, for instance, in the 
adrenergic neurons innervating the pancreatic islets (Sundler and Bottcher, 
1991). 
1.3.2 NPY in Pancreas 
In addition to its presence in the intrapancreatic neurons, NPY has 
also been found to be produced locally in islet cells. Recent studies have 
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demonstrated that NPY co-exists with glucagon and insulin in prenatal 
stage, and in adult cells, it colocalizes predominantly with glucagon 
(Teitelman et al., 1993). Furthermore, NPY immunoreactivity and gene 
expression have been reported in rodent islet cells in studies using 
immunocytochemical and in situ hybridization techniques (Myrsen and 
Sundler, 1995a; Myrsen et al., 1995b). Most recently, similar findings 
have been obtained in human islets (Bennet et al., 1996). Therefore, it is 
evident thatNPY is also a local islet peptide and a possible paracrine role 
o fNPY has been suggested. 
1.3.3 NPY and Islet Hormones 
Due to its presence in intrapancreatic neurons and local production 
in pancreas, NPY has been postulated to be a regulator of islet hormone 
secretion. During the last decade, studies on action of NPY on insulin and 
glucagon have been performed. However, inconsistent results were 
obtained when different study models were used. For instance, in a study 
using living rat, when NPY antisense oligonucleotides was introduced to 
the arcuate nucleus in the brain, circulating level of insulin was reduced 
(Akabayashi et al., 1994). In another whole animal model, NPY injected 
intravenously reduced glucagon secretion but did not affect insulin 
secretion (Pettersson et al., 1987). In contrast, it has been reported that 
islet hormone secretions were not affectedby NPY in perfused pancreas in 
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dog Punning et al., 1987) and pig (Holst et al., 1989), while in rat insulin 
secretion was only slightly inhibited (Skoglund et al , 1991). 
Nonetheless, more consistent results were obtained in perifused 
islet systems. Insulin release was inhibited by NPY in human (Bennet et 
al.，1996)，rat O^ang et al., 1994) and mouse (Opara et al., 1990). 
However, only the latter study has simultaneously reported the action of 
NPY on glucagon release. Li that study, NPY stimulated the secretion of 
glucagon by almost 200 % at elevated glucose level. At basal level of 
glucose, glucagon secretion was also stimulated but the effect was less 
pronounced. Taken together, NPY may act directly on the pancreas as a 
modulator of islet hormone secretions. The mechanism of action of NPY 
remains unclear and further studies are required to elucidate this. 
1.4 Synthesis and Secretion 
The pathway of synthesis and release of a secretory protein is well 
established as illustrated in Figure 1.5. Transcription is the first step and 
results in the production of the mRNA transcripts. During the journey 
from nucleus to rough endoplasmic reticulum ^:R), maturation of mRNA 
transcripts take place. While new mRNA molecules are being transcribed, 
existing molecules are being degraded. The net accumulation of mRNA, 
described as the steady-state, is achieved by elevating transcription rate as 
well as enhancing the stability of the molecules. The mRNA transcripts 
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translated into precursor which is then processed in.the 
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are later translated into precursor protein in a process known as 
translation, which takes place on the rough ER. Afterwards, the 
precursors are processed into mature proteins and are packaged into 
secretory granules in the Golgi apparatus. Assuming that the steady state 
o fmRNA is maintained, an increase of transcription can lead to an increase 
of biosynthesis of the gene product. 
The final discharge of the secretory granules is an independent 
process and is triggered upon stimulation. Calcium is an important second 
messenger and is a necessary component ofthis regulated-exocytosis. The 
pathway of stimulated insulin release in the pancreatic B cells has been 
well studied and an example of glucose-induced insulin secretion is 
illustrated in Figure 1.6. The product of glucose metabolism, ATP, 
induces closure of the ATP-sensitive potassium channels, resulting in a 
membrane depolarization which in tum activates the voltage-dependent 
calcium channels. Opening of calcium channels leads to an influx of Ca�+ 
and thus promotes exocytosis of insulin-containing secretory granules. In 
addition, interaction with other messengers such as inositol trisphosphate 
(rP3), diacylglycerol (DAG) and cAMP are involved in the stimulus-
secretion coupling, as discussed in several reviews (Prentki and 
Matschinsky, 1987; Zawalich and Rasmussen, 1990; Efendic et al., 1991; 
Holz and Habener, 1992). n>3 and DAG are the secondary messengers of 
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Figure 1.6 Diagramatic representation of glucose-stimulated insulin 
release from pancreatic B cells. ATP produced from 
glucose metabolism induces closure of ATP-sensitive K+ 
channels, resulting in membrane depolarization and Ca�+ 
influx. Elevated cytosolic Ca�+ level activates regulated-
exocytosis of insulin granules. OVIodified from Holz and 
Habener, 1992, Trends in Biochemical Sciences，17:388-
393) 
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calcium channels on the internal membranes and leads to a Ca�+ efflux from 
intracellular store, thus elevating cytosolic Ca�+ level. Protein kinases 
activated by DAG and cAMP may also be involved in the process by 
phosphorylating multiple targets such as the ion channels in the exocytotic 
machinery. 
Above all, stimulation of exocytosis is coupled with an increase in 
cytosolic Ca2+ level, which can be derived from both external and internal 
sources, as a result ofthe overall interaction of multiple signal transduction 
pathways triggered by regulatory hormones. 
1.5 Objectives of Study 
The presence of NPY in the central nervous system and its local 
production in pancreatic islets, in conjunction with the reported 
stimulatory actions on glucagon release and inhibitory actions on insulin 
release, have raised the possibility of NPY as a neuroendocrine and 
paracrine modulator of islet hormones. It has generally been believed that 
NPY acts directly on pancreatic B cells to suppress insulin release. The 
stimulatory effect on glucagon, however, has been believed to be indirect 
and secondary to the suppression of insulin. Therefore, the primary 
objective ofthis study is to investigate whether NPY has any direct effect 
on A cells. 
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To eliminate any influences from the nervous system and other 
endocrine and paracrine factors, the cell line model is employed. Two islet 
cell lines, the glucagon-producing InRlG9 cell line and the insulin-
producing Rinl056A cell line，are utilized in this study. The former is 
derived from hamster and has been characterized to be predominantly 
glucagon-producing fDrucker et al, 1988b). The post-translational 
processing ofglucagon from these cells is similar to that from pancreatic A 
cells and subsequent passages do not change their phenotypes 
substantially. And in order to study the effect o f N P Y on the expression 
ofinsulin, the Rinl056A cell line is utilized. It is a subclone of a rat islet 
cell line originally derived from radiation-induced transplantable insulinoma 
and expresses essentially insulin and somatostatin (Gazder et al, 1980). It 
also expresses glucagon, and yet the post-translational processing 
resembles the intestinal L cells rather than pancreatic A cells (Philippe et 
al, 1986; Tucker et al, 1996). Therefore, it may not be an appropriate 
model for studying the pancreatic expression ofglucagon. 
The level of regulation of hormone secretion may consist of two 
parts: synthesis and release. However, whether NPY stimulates glucagon 
secretion from A cells by activating the synthesis or exocytosis of the 
hormone remains unclear. Hence, we will examine the effect of NPY on 
mRNA expression ofglucagon as well as insulin by Northern blot analysis. 
Furthermore, as calcium is a necessay component of exocytosis of 
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secretory granules, we will also investigate the effect o f N P Y on cytosolic 
calcium levels using confocal laser scanning microscopy. 
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CfiapUr 2 
9^aUriais & MetHods 
2.1 Effects of NPY on Islet Gene Expression 
2.1.1 Tissue Culture 
A. Materials 
The cell lines were generous gifts of Dr. D. J. Drucker (Toronto, 
Canada). Synthetic NPY were purchased from Peninsula. Rosewell Park 
Memorial Institute 1640 (RPMI) medium, Dulbecco's Modified Eagle's 
Medium (DMEM), Hank's Balanced Salt Solution (HBSS), fetal bovine 
serum (FBS), penicillin, streptomycin, fungizone and trypsin were 
purchased from Gibco BRL. Culture dishes and disposable conical tubes 
were obtained from Falcon. Cryo vials and disposable pipets were 
purchased from Nalgene and Costar respectively. 
B. Maintenance and Passage 
InRlG9 cells were maintained in RPMI medium whereas Rin 
1056A in DMEM. Monolayer of cells were grown on 100 mm culture 
dishes by standard tissue culture techniques ^VlcAteer and Davis, 1994). 
The medium contained 11 mM glucose and was supplemented with 10% 
(v/v) FBStogether with 100 U/ml ofpenicillin, 100 ^ig/ml of streptomycin 
and 25 i^gAnl offungizone. The cells were cultured at 37 °C in 5% of CO2 
in humidified atmosphere. Culture medium was replaced with fresh one 
every three to four days. 
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後 i •1 
： Passage of cells was performed when the cells were confluent. In 
； brief, cells were washed twice with 3 ml of calcium and magnesium free 
d 
HBSS to remove dead cells. Then 2 ml of trypsin with 0.25 M of EDTA i j 
was added and incubated at room temperature for about two minutes. 
I Trypsinization was terminated by adding same volume of fresh medium 
with FBS. The cells were detached from the plate by pipeting up and 
. 
down and transferred to a conical tube. After centrifugation at 1,000 x g 
for 5 minutes, the cell pellet was initially resuspended in 1 ml of fresh 
medium and appropriate dilution was subsequently made. Generally 2 x 
lC)6 ofcells were seeded to a 100 mm plate for maintenance of the cell lines; 
or 2 X 107 of cells were seeded to 60 mm plates for subsequent 
experiments. Experiments were done when cells were about 80 % 
confluent, which might take two to three days. 
Early batches of cells were cryopreserved and stored in liquid 
nitrogen. Cells were detached by trypsinization as described earlier. The 
cell pellet was initially resuspended in 1 ml of fresh medium with 10% 
FBS, and same amount of freezing medium was then added dropwise. The 
freezing medium contained 40% (v/v) of FBS and 40% (v/v) of dimethyl 
sulfoxide and was cooled down to ice-cold temperature prior to addition. 
Cell suspension was divided into 1 ml aliquots in cryo-vials which were 
then placed in the pre-cooled StrataCooler Cryo preservation module 
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(Stratagene). The cryo presevation module was stored in at -80^C 
overnight and the vials were then transferred to liquid nitrogen for storage. 
C. Experimental Protocol 
Synthetic NPY was dissolved in culture medium containing 10% 
FBS to a stock concentration of 10 '^ M. It was divided into aliquots and 
stored at -20 °C. Prior to being used in the experiments, it was thawed on 
ice. 
Cells of80% confluency were washed twice with HBSS to remove 
cell debris and incubated with 2 ml fresh medium containing NPY at final 
concentrations of 10 '^ ^ M, 10 ] � M , 10 ‘^  M and 10 ‘^  M. The NPY-
containing medium was prepared by serial dilution from the stock. 
Control experiments were done in the absence of NPY. The cells were 
incubated under standard conditions for 2, 4, 8 and 16 hours before total 
RNA extraction. Experiments were done in duplicate and repeated several 
times. 
2.1.2 Total RNA Isolation 
A. Materials 
Water-saturated phenol was obtained from Gibco BRL. Absolute 
ethanol, isopropanol, chloroform and isoamyl alcohol were purchased from 
Merck, while diethyl pyrocarbonate (DEPC) was from Sigma. The 
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FastPrep system, which includes the FastPrep FP 120 instrument and 
1 FastRNA kit, was a product of Bio 101，Inc. 
1 
I 
B. Extraction Using FastPrep System 
j 
i 
Total RNA was extracted by using the FastPrep system. After 
1 
incubation with NPY, the cells were rinsed with phosphate buffered saline 
(PBS). 200 i^l of fresh PBS was then added and cells were scraped and 
transferred to the FastPrep green tubes, which already contained the lysing 
matrix, 500 i^l ofchaotropic RNA stabilizing reagent, 500 U^ of phenol acid 
reagent and 100 i^l ofchloroform isoamyl alcohol. All these reagents were 
either supplied with the kit or prepared according to manufacturers 
instructions. 
The tubes were then placed in the FastPrep FP 120 instrument and 
processed at a speed rating of6.5 for 30 seconds. They were chilled on ice 
for 5 minutes before being centrifuged at 10,000 rpm in a refrigerated micro 
centrifuge for 20 minutes. After centrifugation, the upper phase was 
transferred to a fresh microtube without disturbing the interphase. This 
upper phase was re-extracted by 500 i^l of chloroform isoamyl alcohol. 
The mixture was vortexed for 10 seconds and centrifuged for another 5 
minutes at room temperature. Again the upper phase was carefully 
transferred to a fresh microtube and 500 i^l of DEPC-treated-i sopropanol 
precipitation solution was added. Precipitation was done at -20 °C for at 
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丨 After centrifugation, the supernatant was decanted and the pellet 
( 
� was washed with 500 i^l of salt-ethanol wash solution and briefly 
j 
I centrifuged. The supernatant was removed with small bore pipet tip and 
] 
;| 
I the pellet was dried by speed vac for 3 minutes. Finally, the pellet was 
.1 
.1 
! resuspended in 50 i^l ofDEPC-treated water and kept at -80 ®C. 
I 
i 
I C. Quantification of RNA 
The concentration of total RNA was measured by ultra-violet 
spectrophotometry. In brief, 5 ^1 o f R N A was diluted in 1 ml o fDEPC-
treated water and transferred to a quartz cell. The Ultrospec IH 
spectrophotometer fPharmacia Biotech) was used. Concentration of 
RNA was estimated by measuring the absorbance at wavelength of 260 
nm, For calculation, one absorbance unit approximately equals to 40 昭 of 
RNA per ml. The purity, with respect to DNA contamination, was 
estimated by the ratio of absorbance at 260 nm to that at 280 nm. 
D. Preparation of Reagents 




Chloroform was mixed with isoamyl alcohol in a 24 to 1 ratio 
(v/v). It was stored in a closely-capped bottle at room 
temperature. 
j 
2. DEPC-treated water 
j 
I 
j Diethyl pyrocarbonate (DEPC) was added to deionized water to 
1%. The solution was vigorously stirred for 15 minutes by a 
magnetic stirrer and incubated at 37 °C overnight. It was then 
autoclaved at 1 bar of pressure at 115 °C for 25 minutes. All 
materials which required autoclaving were autoclaved in the same 
conditions. 
2.1.3 Northern Blot Analysis 
A. Materials 
Agarose was purchased from Gibco BRL. Formaldehyde, 
formamide and 3-0S^-morpholino)propanesulfonic acid (MOPS) were 
obtained from Sigma. RNase away was obtained from Molecular Bio-
Products. The Nytran-N membrane was purchased from Schleicher & 
Schuell. Labeling reaction was performed using the Gibco BRL Random 
Primers DNA Labeling System while purification of labeled probes was 
3 2 
done by Stratagene NucTrap Probe Purification Column. Redivue [a-
P]dATP and Rapid-Hyb buffer were obtained from Amersham. X-




B. Formaldehyde Gel Electrophoresis 
Total RNA was size-fractionated under denaturing condition of 
•1 j 
5 
formaldehyde by agarose gel electrophoresis. The comb, gel tray as well as 
\ the gel tank were thoroughly wiped with RNase decontaminator (Rnase 
i 
I 
Away, Molecular Products) and rinsed with DEPC-treated water to 
remove RNase. 
To cast a 1.2% gel, agarose was melted in DEPC-treated water. 
When it was cooled down to 60�C，10X MOPS buffer and formaldehyde 
were added to IX and 2% respectively. The gel mix was then poured into 
the tray with both ends sealed. Air bubbles, if any, was removed using a 
disposable pipet tip and the comb was inserted afterwards. The gel was 
allowed to solidify at room temperature for about an hour, after which the 
comb and seal of gel tray were carefully removed. The gel was then 
submerged in the tank filled with the IX MOPS running buffer. 
For sample treatment, 15 ^ig of total RNA was dried by speed vac 
and reconstituted in DEPC-treated water. Deionized formamide, 
formaldehyde and 10X MOPS at final concentrations of 50%, 6% and 
0.5X respectively were added and the mixture was incubated at 65 °C for 
10 minutes. Prior to loading, 5 [i\ ofloading dye was added. The samples 
were then loaded carefully into the wells and the gel was run at a constant 





； To visualize the RNA, the gel was stained with ethidium bromide 
\ I 
at a final concentration of0 .5 ^ig/ml in DEPC-treated water with vigorous 
j 
！ shaking for 10 minutes. Ethidium bromide binds to nucleic acids and 
f i 
� fluorescence upon uv-transillumination. Prior to being transferred onto 
I 
I nylon membrane, the gel was destained in DEPC-treated water for at least 
15 minutes. 
C. Transfer onto Nylon Membrane 
Total RNA was transferred onto nytran-N in 10X SSC buffer using 
the Pharmacia VacuGene XL Vacuum Blotting System. The blotting 
system uses a low pressure vacuum to transfer RNA to membranes. The 
pump was connected to the blotting unit via a liquid trap. The nytran-N 
membrane, which had been soaked in transfer buffer for 15 minutes, was 
placed in between the porous screen and the plastic mask. Then the frame 
on the top of the blotting unit was secured by tightening the four locking 
clamps. Afterwards, the gel was carefully slided onto it. Vacuum pump 
was then turned on and once it was on, transfer buffer was poured in 
immediately. The transfer procedure was run at constant pressure at 50 
mbar for two hours. 
After the transfer, the blotting system was dissembled and the 
membrane was briefly wiped dry on a 3 mm Whatman paper. The RNA 
were then immobilized by uv-crosslinking using the UV Stratalinker 1800 
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(Stratagene). The autocrosslink mode was used where the membrane was 
subjected to an exposure of 1200 micrqjoules for approximately 50 
seconds. The blots were stored and remained stable at 4 °C. 
I D, Labeling of cDNA Probes 
The cDNA probes were radiolabeled as previously described 
^"einberg and Vogelstein, 1983) and were prepared by using the Random 
Primers DNA Labeling System. For each labeling reaction, 25 ng of cDNA 
was dissolved in 23 i^l ofautoclaved deionized water and was denatured at 
100 °C for 10 minutes. It was immediately chilled on ice after boiling. 
Reaction mixture consisting of 2 ^1 of dCTP solution, 2 i^l of dGTP 
solution, 2 i^l o fdTTP solution and 15 i^l of the random primers buffer 
mixture was added. A random hexamer was included in the buffer mixture 
as primer. Then, 5 i^l of redivue [a-^^ P]dATP with activity at about 10 
p,Ci/|il was added. Finally, 3 units of Klenow fragment of DNA 
polymerase I was added and mixed gently. The labeling reaction was done 
at room temperature ovemight. 
After the labeling reaction, the probe was purified by the NucTrap 
column. Li brief, the column was pre-wetted with 70 i^l of STE buffer. 
Then the labeling product was loaded and pushed through the column. Un-
incorporated radionucleotides were trapped and the flow through was 





buffer and the flow through was collected again in the same tube. The 
collection tube was spinned briefly and the purified probe was diluted with 
STE buffer to 1 ml. A 5 l^l aliquot was taken and the total radioactive 
counts were measured by the QC.2000 beta-counter CBioScan). The 
specific activity ranged from 2.4 x 10^ to 5 x 10^ cpm per i^g of template 
DNA. 
E. Hybridization and Autoradiography 
Hybridization was performed in the Duo-Therm-Oven (Biometra). 
The blot along with a mesh was rolled and placed in the hybridization tube 
without any air bubbles trapped. For a 15 cm x 20 cm blot, 10 ml of pre-
warmed Rapid-hyb buffer to was added to the tube. The blot was pre-
hybridized at 65 X for halfan hour before the addition of the radiolabeled 
cDNA probe. Prior to addition to the hybridization tube, the probe was 
boiled for 10 minutes and chilled on ice immediately. The probe was added 
along the side of the hybridization tube and hybridization was done at 65 
°C for three hours. 
After hybridization, the blot was washed wtih vigorous shaking in 
500 ml of first wash buffer (2 X of SSC and 0.1 % of SDS) at room 
temperature for 20 minutes. It was subsequently washed with 500 ml of 
second wash buffer (1 X of SSC and 0.1 % of SDS) at 55 °C for 15 




i remained high. The washed blot was wrapped in plastic wrap and 
I autoradiographed against X-OMAT film with an intensifying screen at -80 
i j 





I F. Preparation of Reagents 
1. MOPS buffer, 10X 
The 10X buffer contained 0.2 M of MOPS, 0.05 M of sodium 
acetate and 0.01 M of EDTA. The solution was sterilized by 
autoclaving. After autoclaved, the buffer would tum yellow and 
was stored at room temperature. The IX formaldehyde gel running 
buffer was diluted from stock with DEPC-treated water. 
2. RNA loading dye 
The dye consisted of 1 mM o f E D T A at pH 8.0，0.25 % (w/v) of 
bromophenol blue, 0.25% (w/v) ofxylene cyanol and 50% (w/v) of 
glycerol in DEPC-treatedwater, and was stored at -20 T . 
3. SSC buffer, 20X 
It consisted o f 3 M of sodium chloride and 0.3 M of sodium at p H 
7.0. It was sterilized by autoclaving and stored at room 
temperature. 
4. STE buffer 
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The buffer consisted of 100 mM of sodium chloride, 20 mM of 
Tris at pH 7.5 and 10 mM of EDTA in autoclaved deionized 
water. 
2.1.4 Preparation of cDNA probe 
The cDNA clones ofrat glucagon and insulin were generous gifts of 
Dr. D. J. Drucker (Toronto, Canada) and zebrafish B-actin was a gift ofDr. 
K. M. Chan (Chinese University, Hong Kong). The cDNA clones were 
prepared and manipulated using basic molecular cloning techniques as 
described herein this section. 
A. Materials 
Molecular grade chemicals were obtained from Sigma or Gibco 
BRL. The DH5a strain ofE. Coli. and SOC medium were obtained from 
Gibco BRL. Ampicillin was purchased from Stratagene, while restriction 
enzymes were from either Promega or Boehringer Mannheim. Purification 
o fDNA fragments was performed by using the Bio 101 GeneClean II Kit. 
B. Preparation of Competent Cells 
By standard microbiological techniques, the DH5a strain of E. 
Coli. was streaked on LB agar plate, which was then incubated at 37 °C for 
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i about 16 hours. It was kept at 4 °C and the bacteria remained viable on the 
$ 
1 
j agar for up to two months. 
！ 
1 To prepare competent cells, single colony o f D H 5 a was inoculated 
to 10 ml LB broth and was incubated with shaking at 250 rpm at 37 °C. 
j 
！ After overnight cultivation, 2.5 ml of this bacterial culture was inoculated 
to 250 ml o fLB broth in a 1 L erlenmeyer flask and was grown for another 
I 
2 - 3 hours until the optical density (O.D.) at 600 nm reached 0.4 - 0.5. 
The culture was then chilled on ice for 2 hours and bacterial cells were 
harvested by centrifugation at 5,000 rpm at 4 °C for 20 minutes using a JA 
14 rotor and Beckman J2.21 high speed centrifuge. 
After centrifugation, supernatant was decanted and pellet was 
initially resuspended in 10 ml ofice-cold trituration buffer and then diluted 
to 250 ml with the same buffer. The cell suspension was incubated on ice 
for 45 minutes before collecting cells by centrifugation at 3500 rpm at 4 °C 
for 10 minutes. The cell pellet was resuspended in 25 ml of ice-cold 
trituration buffer and 5.8 ml of sterile 80% (v/v) glycerol was added 
dropwise with gentle swirling. 
Competent cells were divided in 1-ml aliquots and frozen by dry 
ice. The frozen cells were stored at -80 °C. 
C. Transformation 
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The cDNA clones of rat glucagon, rat insulin and zebrafish B-actin 
were used to transform the competent DH5a. After being thawed on ice, 
100 i^l ofcompetent DH5a was added to 1 [i\ (or 1 ^ig) of plasmid DNA 
and mixed gently in a 14 ml round bottom tube. This mixture was chilled 
on ice for 30 minutes and was then heat-shocked at 42 ®C for 2 minutes 
and back on ice immediately, followed by addition of 500 i^l of SOC 
medium.. After an hour o f 3 7 °C incubation with shaking at 300 rpm, it 
was poured and spreaded evenly on an LB-ampicillin plate. The plate was 
incubated at 37 °C ovemight and then stored at 4 °C. 
D. Plasmid DNA Isolation 
A single colony of transformant was inoculated in 3 ml of LB 
medium with the addition of ampicillin at a final concentration of 100 
^lg/ml and incubated with shaking at 200 rpm at 3 7 � C . After 8 hours, the 
whole culture was used to inoculate 200 ml of LB medium with ampicillin 
and was grown overnight. 
On the following day, cells were harvested by centrifugation at 
8,000 rpm at 4 °C for 5 minutes using a JA 14 rotor and Beckman J2.21 
high speed centrifuge. Supernatant was decanted and pellet was 
resuspended in 20 ml of ice-cold solution A, followed by the addition of 
40 ml of freshly-prepared solution B. After incubation on ice for 10 




15 minutes. The mixture was then centrifuged at 10,000 rpm at 4 °C for 
10 minutes. The supernatant was filtered through a piece of cheese cloth 
and was collected in a clean centrifuge bottle. Two volumes of absolute 
alcohol was added and kept at -20 °C for 20 minutes. The mixture was 
i 
centrifuged again for 20 minutes. The supernatant was discarded and the 
pellet was resuspended in 5 ml o fTE bufFer, followed by adding 2.5 ml of 
7.5 M ammonium acetate. It was put on ice for 30 minutes and then 
centrifuged under the same conditions for another 10 minutes. The 
supernatant was collected and 2 volumes of absolute ethanol was added, 
and was kept at -20 °C for 20 minutes. Finally, plasmid DNA was 
collected by centrifugation at 11,000 rpm at 4 °C for 15 minutes. 
The DNA pellet was resuspended in 2 ml o fTE and divided into 4 
aliquots. To each aliquot, 5 U^ of50 |ig/ml RNase A，5 i^l of 5 M sodium 
chloride, and 5 i^l of 10 U/|il RNase T1 and was incubated at 37 °C for 30 
minutes. Then, 5 [il of proteinase K at a concentration of 10 mg/ml and 10 
l^l of 10% SDS were added and incubated at 37 ®C for another 30 minutes. 
The enzymes were then extracted with 1 volume of buffer-
saturated phenol:chloroform:isoamyl alcohol (25:24:1) and spinned in a 
refrigerated microcentrifuge for 5 minutes. The supernatant was carefully 
transferred to a fresh microtube and was extracted again with one volume 
of chloroform. Again it was spinned for 2 minutes and the supernatant 
was collected. To it, 0.5 volume of ammonium acetate was added and the 
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DNA was precipitated with 2 volumes of absolute ethanol at -20 °C for 20 
minutes. It was spinned at 11,000 rpm at 4 °C for 30 minutes. The pellet 
was collected and washed twice with 200 i^l of 70% (v/v) ethanol. Finally 
the plasmid DNA was resuspended in 250 i^l of TE buffer altogether and 
stored at -20 X . 
E. Restriction Enzyme Digestion 
After the isolation of plasmid DNA from the bacterial host, the 
cDNA inserts were released from the vector by restriction enzymes. In 
the digestion mixture, 25 |lg of DNA of each clone was cut with the 
appropriate restriction enzymes in the corresponding buffering systems. 
The rat glucagon cDNA clone, carried by a pGEM vector, was cut 
with Pst I and Sac I using Buffer A and the size of this fragment was about 
1,000 bp. The rat insulin cDNA clone, carried by pBR322, was cut with 
Hind m using Buffer B and the size was about 400 bp. Finally the 
zebrafish B-actin cDNA clone, carried by pUC 18，was cut with BamH I 
and EcoR I using Buffer B to generate a 800 bp fragment. 
The digestion volume was 200 i^l and 50 units of each enzyme was 
used for each reaction. Twenty-p,l of the corresponding buffer was 
included and autoclaved deionized water was added to make up the volume 
to 200 |ji. The digestion reaction was carried out at 37 °C for 16 hours. 
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F. Agarose Gel Electrophoresis 
The products of restriction digests were subjected to agarose gel 
electrophoresis using a mini submarine apparatus. 
The casting of gel was similar as described earlier, except that the 
volume ofgel mix was 50 ml and the buffering system was 0.5X TBE. In 
addition, ethidium bromide was added to the gel at a concentration of 0.5 
jj,g/ml. The gel was allowed to set for half an hour and then submerged in 
the tank filled with the 0.5X TBE running buffer. 
One hundred microliters of the digested products were mixed with 
20 i^l o fDNA loading dye and loaded onto the gel carefully. The gel was 
run at 100 V for about one hour and the DNA was visible upon uv-
transillumination. The slice ofgel containing the insert fragments were cut 
with a scalpel and stored in a microtube. Purification of DNA fragments 
was done afterwards. 
G. Isolation of DNA Fragments 
Slice of gel containing the desire fragment was chopped into small 
pieces and dissolved in 675 i^l of sodium iodide, with the addition of 75 \il 
of TBE modifier. The mixture was incubated at 60 °C for 10 minutes to 
enhance dissolution. When the slice was completely dissolved, 10 \i\ of 
the Glassmilk suspension was added and vortexed for 10 seconds. After 
incubated at 37 °C for 15 minutes, it was briefly spinned to collect the 
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pellet, which was then washed three times with 400 i^l of New Wash 
solution. The pellet was dried briefly in air and 10 i^l of TE buffer was 
added to elute the DNA. It was vortexed and centrifuged briefly to collect 
the supernatant. Elution of DNA was repeated for 3 times to enhance 
yield and the purified DNA fragment, 40 fil in total, was stored at - 2 0 � C 
and ready for labeling. 
H. Preparation of Reagents 
I. 1 Kilo base-pair (1 Kb) DNA marker 
The 1 Kb DNA marker was purchased from Gibco BRL and was 
diluted four times in dilution buffer, which contained 10 mM of 
Tris, 50 mM of sodium chloride and 100 _ of EDTA. The 
marker was stored in 20 [i\ aliquots at -20 °C. 
2. LB or LB-ampicillin agar plates 
The LB agar consisted of L5% (w/v) agar, 1% (w/v) peptone, 0.5% 
(w/v) yeast extract and 10 g sodium chloride in each liter of 
deionized water at pH 7.4 and was sterilized by autoclaving. To 
pour plates, it was cooled down to 55 X . Li the case of LB-
ampicillin plates, ampicillin was added to a final concentration of 
100 \iglm\. About 25 ml of the liquid agar was poured into each of 
a 100-mm sterile disposable petri dish and was allowed to cool 
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1 down and solidify at room temperature. The plates were stored at 
4 °C and ready for use for up to two months. 
3. LB broth 
The LB broth consisted of 1% (w/v) peptone, 0.5% (w/v) yeast 
extract and 10 g sodium chloride in each liter of deionized water at 
pH 7.4. The broth was sterilized by autoclaving and stored at 
room temperature. 
4. Solution A 
It consisted of50 mM ofglucose, 50 mM ofTris at pH 8.0 and 10 
mM ofEDTA at pH 8.0 in deionized water. The solution was 
sterilized by autoclaving and stored at 4 T . 
5. Solution B 
This was prepared freshly by mixing 10 ml of 2 M sodium 
hydroxide and 10 ml of 10% SDS in 80 ml of autoclaved deionized 
water. It was kept at room temperature to avoid precipitation. 
6. Solution C 
To 60 ml of 5 M ofpotassium acetate, 11.5 ml of glacial acetic acid 
and 28.5 ml ofautoclaved deionized water were added and stored at 
4 � C . 
7. STET buffer 
It contained 8% (w/v) sucrose, 5% (v/v) triton X-100, 50 mM 







The solution was sterilized by filtering through 0.22 ^lM 
I disposable filters and stored at 4 °C. 
I 8. TBE buffer, 10X 
^ 
1 
I For each liter, 108 g ofTris, 55 g of boric acid and 40 ml of 0.5 M 
of EDTA at pH 8.0 were dissolved in dd water. It was stored at 
room temperature and diluted to IX to obtain the DNA gel running 
buffer. 
9. TEbufFer 
The buffer consisted of 10 mM ofTris and 0.1 mM of EDTA at 
pH 8.0. It was sterilized by autoclaving and stored at room 
temperature. 
10. Trituration bufFer 
The buffer consisted of 100 mM of calcium chloride, 70 mM of 
magnesium chloride and 40 mM of sodium acetate at pH 5.5 in 
deionized water. It was prepared freshly and sterilized by filtering 
through 0.22 [im for each use. 
11. Lysozyme 
The working concentration was 10 mg/ml in autoclaved deionized 
water. It was kept in 0.5 ml aliquots at - 20 °C. 
12. Proteinase K 
The working concentration was 10 mg/ml in autoclaved deionized 
water. It was kept in 0.5 ml aliquots at - 20 °C. 
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13. RNaseA 
The enzyme was diluted 10 times in enzyme dilution buffer to a 
working concentration of50 l^gAnL It was kept in 0.5 ml aliquots 
at - 20 °C. The enzyme dilution buffer consisted of 10 mM of 
Tris, 5 mM of calcium chloride and 50% (v/v) of glycerol and pH 
was adjusted to 7.0, as suggested by manufacturer. 
14. RNase T1 
The enzyme was diluted 10 times in autoclaved deionized water to 
the working concentration of 10 U/^il. It was kept in 0.5 ml 
aliquots at - 20 T . 
2.1.5 Data Analysis 
The autoradiograms were quantified and analyzed by laser 
densitometry OVlolecular Dynamics) with the aid of the taageQuant 
software. The glucagon mRNA levels were normalized with respect to the 
level of actin and expressed as a percentage of the control for each 
experiment, which was assigned a mean value of 100 %. Statistical 
analysis was performed by student's t test using SigmaStat software 
(Jandel Scientific) and the significance level was denoted as * for P < 0.05. 
2.2 Effects of NPY on Cytosolic Calcium Dynamics 
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2.2.1 Tissue Culture 
In general, maintenance and passage ofInRlG9 and Rinl056A cells 
were the same as previously described, except that the cells were grown on 
25-mm cover slips (Fisher Scientific). Cover slips were placed on a sterile 
60 mm culture dish and sterilized by exposure to ultra-violet light for 
fifteen minutes. After UV-irradiation, they were left in the lamina flow for 
5 minutes. Afterwards, 3 ml of cell suspension containing about 1 x 10^ 
cells was directly added on them. The dish was gently swirled to evenly 
distribute cells over the cover slips. The conditions of cell culture were the 
same as the normal maintenance of the cell line and experiments were done 
two days after subculture. 
2.2.2 Confocal Laser Scanning Microscopy 
A. Materials 
The Bio-Rad confocal laser scanning microscope system (MRC 
1000) was employed. Cover slips were obtained from Fisher Scientific. 
Fluo-3 acetoxymethyl ester and Pluronic F-127 were purchased from 
Molecular Probes, whereas all chemicals making up SJF were obtained 
from Sigma. Synthetic peptides QS[PY, PYY and PP) were products of 
Peninsula. Forskolin, thapsigargin and nifedipine were obtained from RBI. 
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I B. Loading of dye 
I The cover slip was used as the bottom of an open chamber which 
I consisted of a threaded silicon rubber ring and a threaded stainless steel 
ring. The cover slip was secured in the chamber by tightening the threads 
and the bottom of it was wiped with a tissue paper to remove any 
attached cells. And then cells on the cover slip were rinsed twice with 
bicarbonate-buffered synthetic interstitial fluid (SEF), which consisted of 
145 mM ofNa+; 3.5 mM ofK+; 1.5 mM of Ca]+; 0.69 mM ofMg2+; 114 
mM of Cr; 26.2 mM ofHCC^; 1.7 mM ofPO4 2.; 0.69 mM of SO4 h 9.6 
mM of gluconate; 5.55 mM of glucose and 7.6 mM of sucrose and was 
prepared freshly on the day of experiment. The cells were subsequently 
incubated with 2 ^iM of the cell permeant form (acetoxymethyl ester) of 
fluo-3 supplemented with Pluronic F-127 in SJF at room temperature for 
30 minutes. Supplementation of the detergent Pluronic F-127 is known to 
aid dye uptake by the cells probably by forming readily avaiblable 
micelles. Since the dye is light-sensitive, the cover slip was kept in dark 
during loading. Afterwards, cells were washed with SJF for another three 
times and incubated in the same buffer for at least 30 minutes prior to 
measurements of cytosolic calcium to allow intracellular de-esterification 
of the dye to complete. 
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B. Cytosolic Calcium Measurement 
A 60x high numerical aperture (1.3) oil immersion objective was 
used in conjunction with minimum laser intensity (0.3 - 1 %) to minimize 
photobleaching and cell damage. The excitation wavelength of fluo-3 is 
506 nm while its emission wavelength is 526 nm. 
During the experiments, the cells were continuously perfused with 
SIF at a rate of 1.5 ml per minute except during treatments of testing 
substances. The advantages of perfusing the cells continuously are to 
avoid accumulation ofmetabolites and also to provide a steady supply of 
nutrients to the cells. During treatments, the perfusion system was tumed 
off and NPY or other testing substances were added directly to the 
chamber immediately. To remove the peptide-containing bufFer, perfusion 
was resumed and continued until next introduction of test substances. 
Experiments on single cover slip were finished within an hour. 
C. Preparation of Reagents 
1. Fluo-3 
Stock concentration ofthe dye was 3 mM in DMSO and stored at 
-20 °C. The dye is light-sensitive and therefore is stored in the 
dark. Prior to loading, it was freshly diluted from the stock to 2 i^ 
M with SJF and remained in the dark. 
2. Sff 
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Synthetic interstitial fluid (Sff) was prepared freshly on the day of 
experiment. The pH was maintained at 7.4 and the buffer was 
bubbled with 95% oxygen and 5% carbon dioxide throughout the 
experiments. 
3. Dissolution o fNPY 
Synthetic NPY was dissolved in SJF to a stock concentration of 10 
-^M and stored in 20 |il aliquots at -20 °C. Prior to being used in 






3.1 Studies on Islet Gene Expression 
i 1 
.4 
i 3.1.1 Effect of NPY on Proglucagon mRNA Expression 
j' 
A. Effect at 11 mM Glucose 
i ^ 
I In the presence of 11 mM glucose, InRlG9 cells were treated with 
synthetic NPY at final concentrations of 10 ]2 M, 10 - i � M , 10 '^  M and 
i 
i 
10 -6 M for 16 hours. Under these experimental conditions, NPY induced 
j , 
a dose-dependent increase of proglucagon mRNA level with respect to 
control level, whereas the mRNA level of actin was unchanged. A 
representative autoradiogram is presented in Figure 3.1. The 
autoradiograms were quantified by laser densitometry and the 
densitometric measurements have been normalized with the corresponding 
actin level on the same blot and are expressed as a percentage of control. 
t i response to increasing doses ofNPY, an increasing trend of proglucagon 
expression was observed OFigure 3.2). The values shown are mean 土 s.e.m. 
(n=13). At 10 -6 M ofNPY, the mRNA level of proglucagon was elevated 
by more than 20% when compared to the control (P < 0.05). 
To establish the time course of the action of NPY, the cells were 
incubated with synthetic NPY in the presence of 11 mM glucose for 2, 4， 
8 and 16 hours before total RNA extraction. After 2, 4 and 8 hours of 
NPY treatments, changes of proglucagon mRNA levels compared to the 
control level were minimal O^igure 3.3). However, after 16 hours of 
treatment, NPY induced a gradual increase of proglucagon mRNA levels 
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while actin level remained unchanged. Figure 3.4 shows the graphical 
representation of the time course of the effect o fNPY from 2 to 8 hours. 
B. Effect at 5 mM Glucose 
In the presence of 11 mM glucose, NPY induced a dose-dependent 
increase of proglucagon mRNA expression in the M U - G 9 cells. The 
effect of NPY at 5 mM glucose was also studied. Cells were incubated 
with NPY in medium containing 5 mM glucose for 2，4, 8 and 16 hours. 
At the time points studied, change of proglucagon mRNA level，when 
compared to the control, was minimal OFigure 3.5). A comparison of the 
effect of NPY on proglucagon mRNA expression at 5 mM and 11 m M 
glucose is illustrated in Figure 3.6. After 16 hours of treatment, NPY did 
not affect the level of proglucagon mRNA in the presence of 5 m M 
glucose, but it induced an increase at 11 mM glucose in a dose-dependent 
manner. 
3.1.2 Effect ofNPY on Proinsulin mRNA Expression 
The effect o fNPY on proinsulin mRNA level was examined in the 
Rin 1056A cells. Likewise, the cells were treated with NPY at final 
concentrations o fo f 10 ]2 M，10 - � M，10 "^  M and 10 '^  M for 4，8 and 
16 hours. The mRNA levels of proinsulin were not affected by NPY at 
the time points studied, both in the presence of 5 mM glucose and 11 mM 
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glucose OFigure 3.7). 
3.1.3 Effect of PYY, PP and FSK on Proglucagon Expression 
Peptide YY (PYY) and pancreatic polypeptide (PP) are 
structurally-related peptides o fNPY. To examine whether the effect of 
NPY on proglucagon expression is specific, the actions of PYY and PP 
were studied. Cells were treated with each peptide at final concentrations 
of 10 -12 M，10 -10 M, 10 -8 M and 10 '^  M in the presence of 11 m M 
glucose. After 2, 4，8 and 16 hours of incubation, neither of the peptides 
induced significant changes of the mRNA levies of proglucagon. The 
autoradiograms for study of the effect of PYY on InRlG9 cells are 
presented in Figure 3.8 while those of PP in Figure 3.9. 
Forskolin (FSK) is an activator of adenylate cyclase and its effect 
on proglucagon mRNA expression was studied following the same 
protocol. In the presence of 11 mM glucose, cells were treated with FSK 
at final concentrations of 10 "^  M, 10 •，M, 10 "^  M and 10 "^  M for 1，4 
and 16 hours. The autoradiograms are shown in Figure 3.10，in which 
increasing trend of proglucagon mRNA expression with respect to the 
control level in response to FSK was observed at the time points studied. 
The graphical representation is illustrated in Figure 3.11. 
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Figure 3.1 A representative autoradiogram of the 
effect of NPY on proglucagon mRNA 
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Figure 3.2 Effect of NPY on proglucagon mRNA level at 
l lmM glucose after 16 hours of treatment. Values 
shown are mean + s.e.m. (n=13) and * denotes 
P < 0.05 by Student's t test. 
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Figure 3.4 Effect of NPY on proglucagon mRNA level at 
11 mM glucose after treatment for (a) 2 hours (n=4); 
(b) 4 hours (n=7); and (c) 8 hours (n=7). 
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at 11 mM glucose at various time points studied. 
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Figure 3.10 Effect of forskolin on proglucagon mRNA 
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Figure 3.11 Effect of forskolin on proglucagon mRNA level at 
11 mM glucose at various time points (n=l). 
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3.2 Studies On Cellular Calcium Dynamics 
3.2.1 Features of InRlG9 Cells 
M U G 9 cells were loaded with fluo-3 and the cellular calcium level 
was monitored by using confocal laser scanning microscope. When the 
cells were perfused with SEF containing 11 mM glucose, 50 - 60% of cells 
exhibited spontaneous calcium oscillation of varying amplitude, frequency 
and regularity as presented in Figure 3.12. Removal of extracellular 
calcium in the perfusion buffer abolished the spontaneous oscillation, and 
the calcium oscillation resumed immediately when the buffer was replaced 
with calcium-containing SJF (Figure 3.13). 
To examine whether the membrane calcium channels are voltage-
dependent, we depolarized the cells with the addition of potassium 
chloride in SH^ containing l l m M glucose. Depolarization by 40mM KC1 
resulted in elevation of calcium level, which was reduced when 3pM co-
conotoxin, an N-type calcium channel blocker was present (Figure 3.14). 
After the removal of co-conotoxin, it appeared that the response to KC1 
depolarization was reduced, probably due to the prolonged effect of co-
conotoxin. Thapsigargin is a known inhibitor of intracellular calcium 
pumps. These pumps transport Ca�+ into the internal stores against 
gradient and blockade of them will result in Ca�+ leakage from the stores. 
In our study, thapsigargin at concentration of O.lpM induced a spike of 
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calcium in non-oscillating cells OFigure 3.15a)，probably by releasing Ca�+ 
from the intracellular stores. In spontaneously oscillating cells, a calcium 
spike was also induced by thapsigargin but the oscillation was terminated 
afterwards OFigure 3.15b). 
3.2.2 Effect of NPY on Cellular Calcium Level 
Li the presence of 1 lmM ofglucose, NPY stimulated glucagon gene 
expression. We therefore studied its effect on cellular calcium level. At 
fmal concentration of l ^ M in Sff containing l l m M glucose, NPY was 
added directly to the perfusion chamber. In non-oscillating InRlG9 cells, 
NPY induced calcium oscillation as shown in Figure 3.16a. Likewise, in 
spontaneously oscillating cells, treatment o f N P Y raised the frequency and 
amplitude of the calcium oscillation of varying regularity OFigure 3.16 b,c). 
This NPY-induced elevation of calcium, however, was markedly reduced 
when extracellular calcium was removed ^lgure 3.17). To identify the 
type of calcium channel involved, the cells were treated with NPY in the 
presence of 5^iM nifedipine, a specific L-type calcium channel blocker. 
As shown in Figure 3.18，NPY elevated calcium level both in the absence 
and presence of nifedipine, suggesting that the calcium influx was via a 
pathway other than L-type channels. When the cells were pretreated with 
0.1 ^ iM thapsigargin, response to NPY was greatly reduced (Figure 3 • 19). 
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The effect ofPYY on cellular calcium level was studied as well. At 
l l m M glucose, PYY at final concentration of l^iM did not significantly 
affect calcium oscillation OFigure 3.20). In contrast, l^iM NPY induced a 
significant elevation of calcium level. 
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Figure 3.15 Elevation of Ca 2+ caused by 0.1 [ M thapsigargin 
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Figure 3.16 Induction of Ca 2+ oscillation by NPY in non-oscillating 
cells (a). Treatment with NPY raised the frequency and 
ampUtude of oscillation in oscillating cells (b,c). 
72 
, 1 1 r ~ 
2 ^ - nominally Ca 2+ free solution “ 
NPY NFY 
180 - H B - " " i - i 
t A 
g 160 _ 广 \ -
j ：： X ^ p A ^ : 
E 100 一 ^ ^ -
80^Ajj _ 
6ol • i ‘ ^ 
0 500 1000 1500 2000 
Time (seconds) 
Figure 3.17 Marked reduction of the response to NPY by removal 
of external calcium. 
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Figure 3.18 Effect of NPY was not significantly affected by 
nifedipine, an L-type calcium channel blocker. 
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Figure 3.19 Reduced effect of NPY by thapsigargin 
pretreatment. 
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Glucose homeostasis is maintained by the timely and coordinated 
secretion of the two endocrine pancreatic hormones, namely glucagon and 
insulin. They are produced by the A and B cells respectively in the islets 
ofLangerhans. The regulation of glucagon and insulin secretions depends 
on multiple factors including those of neural, endocrine, and paracrine 
controls. For example, the primary stimulus for the secretion of insulin 
and glucagon from the endocrine pancreas is the circulating concentration 
of glucose. However, the neural influences to the pancreas also play an 
important part in the regulation of their secretions (for review, see Strubbe 
and Steffens, 1993). Pancreatic secretion ofinsulin from B cells have been 
extensively studied and the mechanisms of its stimulus-secretion coupling 
have been established (for reviews, see Efendic et al., 1991; Zawalich and 
Rasmussen, 1990). In contrast, the regulation of glucagon secretion and its 
mechanisms ofrelease from A cells are less well understood, possibly due 
to the lack ofappropriate experimental models. 
Unlike the B cells, A cells constitute only about 20% of the islet 
cell mass. To isolate adequate numbers of these cells for multiple 
experimental procedures using the same set of cells is technically 
demanding. Furthermore, while several clonal B cell lines are available for 
study of the physiology o f B cells, pure islet A cell lines have yet to be 
established. The hamster islet cell line, InRlG9, is predominantly 
glucagon-producing, and has been utilized as an in vitro model for A cells 
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in many studies investigating the regulation of glucagon gene expression 
and secretion (Philippe, 1989; Matsumura et al., 1992; Gherzi et al, 1994; 
Chertow et al, 1996). The post-translational processing of glucagon from 
InRlG9 cells mimics that from pancreatic A cells and it has been shown 
that subsequent passages of these cells do not change their phenotypes 
substantially ODrucker et al, 1988b). An advantage of using the cell line 
model may include the availability of adequate numbers of cells for 
experimental studies. Furthermore, it is independent of influences from 
neural, endocrine and paracrine origins. However, this is also the limitation 
of the model where the interaction of factors from these origins cannot be 
accounted for. In the present study, the InRlG9 cell line was utilized to 
investigate the action ofNPY on pancreatic secretion of glucagon. 
NPY was first demonstrated in the brain (Tatemoto et al., 1982). 
It is a 36 amino acid peptide and has been found to be the most abundant 
neuropeptide in the central nervous system (Adrian et al., 1983; Allen et 
al.，1984). It has also been found to be present in the nerve fibers 
innervating the islets ofLangerhans (Sundler and B6ttcher, 1991). In the 
CNS，NPY has long been recognized as the key regulator of eating behavior 
and body weight (for review, see Stanley, 1993). The expression o f N P Y 
mRNA is increased in response to fasting in normal rats (Marks et al., 
1992), whereas central administration of NPY results in hyperphagia, 
obesity and hyperinsulinemia. It has thus been postulated to play a 
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pivotal role in the regulation of energy balance and be a key target 
I 
I neuropeptide for leptin in the brain (for review, see Spiegelman and Flier, 
j 
I 1996). Leptin is the product of the obese gene and its major functions are 
j 
I to suppress food intake and decrease body weight. Recessive expression 
！ 
ofthe gene has been linked to obesity, which is related to a host of other 
conditions such as cardiovascular diseases, insulin resistance and type H 
diabetes mellitus. Recent studies have suggested that NPY is the central 
effector of leptin deficiency and is accounted for the obese phenotype 
(Stephens et al., 1995; Erickson et al , 1996b). However in a recent study 
using transgenic knockout mouse model, NPY-deficient animals exhibited 
normal eating behavior and body weight, leading to the speculation that 
NPY may not be the sole regulator of feeding responses ^rickson et al., 
1996a). But as discussed by Stephens (1996), the knockout model may 
have underlying abnomalities and may be phenotypically different from 
other study models, and also a compensatory mechanism may exist. Thus 
the physiological role of NPY and its interaction with other factors in 
controlling food intake and body weight await further clarifications. NPY 
has also been postulated to play a role in the eating disorder and obesity 
observed in diabetic animals. In spontaneously diabetic rats, peptide 
concentration of hypothalamic NPY was significantly elevated OVilliams 
et al., 1989a), whereas in streptozotocin-induced diabetic rats, the 
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hypothalamic NPY levels were substantially augmented (Williams et al., 
1988 and 1989b; White et al., 1990). 
In the pheriphery, however, little is known of the physiological 
actions ofNPY. The findings thatNPY coexists with glucagon and insulin 
in the prenatal stage and adult islets (Teitelman et al., 1993)，together with 
the reported NPY gene expression in the islets from several other studies 
(Myrsen and Sundler, 1995a; Myrsen et al., 1995b; Bennet et al., 1996)， 
suggest that NPY may have a functional role within the islets of 
Langerhans. To clarify the possible actions of NPY on islet hormone 
biosynthesis and release, we have utilized the glucagon-producing islet cell 
line (InRlG9), with specific emphasis on the effect of NPY on 
proglucagon gene expression, in our present study. 
In the study, InRlG9 cells were treated with synthetic NPY (final 
concentrations from 10 ]2 to 10 '^ M) for 16 hours with either 11 or 5 mM 
glucose in the culture medium. In the presence of 11 mM of glucose, NPY 
induced a dose-dependent increase in proglucagon mRNA expression 
compared to the control level by Northern blot analysis, while no changes 
of the mRNA level of B-actin were observed. Quantitation by laser 
densitometry revealed that NPY at a final concentration as low as 10 - � M 
induced the stimulation of glucagon gene expression, and at 10 '^ M, the 
increase was more than 20% higher compared to control (n=13; P<0.05). 
On the contrary, the NPY effect on glucagon gene expression was not 
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detected in the presence of 5 mM of glucose under the same experimental 
conditions. These observations appeared to be contradictory to the 
known inhibitory effect of high glucose on glucagon secretion (Sumida et 
al.，1994). However, as insulin secretion is markedly stimulated at 
elevated glucose level, a mechanism to compensate for the risk ofi ts excess 
secretion may be necessary. Augmentation of the production and release 
ofglucagon can then be a possible mechanism. It is interesting to note that 
it has been reported previously that in the presence of 27.7 mM glucose, 
NPY could reverse the suppressive effect of high glucose on glucagon 
secretion, and significantly stimulated glucagon secretion by more than 
200% (Opara et al., 1991a). The stimulation was less pronounced when 
glucose level was at 5.5 mM. In another report, a gut-derived peptide 
hormone, glucose-dependent insulinotropic peptide or also known as 
gastric inhibitory peptide (G0>), has been found to exert its effect on 
pancreatic islets in a glucose-dependent manner (Opara and Go, 1991b). 
In the presence of 11.1 and 22.2 mM glucose, GEP dose-dependently 
increased the secretion of glucagon significantly in both cases when 
compared with the basal levels. Hence it is possible that NPY may reverse 
the suppressive effect of glucose on glucagon secretion and acts on the 
endocrine pancreas to promote the synthesis and secretion of glucagon to 
safeguard the excess secretion of insulin at elevated glucose level. 
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After treatments for 2, 4 and 8 hours with NPY in the presence of 
11 mM glucose, no significant changes of proglucagon mRNA level were 
detected at all the time points studied, but the NPY stimulated 
proglucagon expression was observable after 16 hours of treatment. The 
time course of our results is not unusual as regulation at the transcription 
level can occur from 1 hour to as long as 48 hours. For instance, it has 
been reported that the inhibition of proglucagon expression by insulin was 
detected for up to 48 hours (Philippe, 1989), while in another study, the 
expression of glucagon stimulated by arginine was only detected after 18 
hours oftreatment (Yamato et al., 1990). We also studied the time course 
of effect o fNPY in the presence of 5 mM glucose. No significant changes 
ofproglucagon mRNA levels were detected at all the time points studied, 
suggesting the non-responsiveness to NPY at this glucose level. Our data 
therefore suggest that the effect of NPY on InRlG9 cells at 11 mM of 
glucose is to promote the increase in mRNA level of proglucagon. NPY 
may exert its modulating stimulatory effect on glucagon secretion via, at 
least in part, the accumulation of proglucagon mRNA. However, it is 
unclear from our results whether the effect of NPY is a result of the 
stimulation oftranscription orthe enhancement of mRNA stability. 
NPY is one of the most conserved peptides across species (for 
review, see Larhammar, 1996a). It also shares high similarities in its amino 
acid sequence with the two structurally-related peptides, namely peptide 
82 
YY OPYY) and pancreatic polypeptide (PP). All of them have 36 amino 
acids and are characterized by their hair-pin structures, the so-called PP-
fold. Hence in order to examine the specificity of the effect of NPY on 
proglucagon mRNA expression, the cells were treated with PYY and PP 
using the same experimental protocol in the study. After treatments for 2, 
4，8 and 16 hours at 11 mM glucose, neither PYY nor PP significantly 
afFected the level ofproglucagon mRNA, suggesting that the action o f N P Y 
on the clonal InRlG9 cell line is specific. Actions o f N P Y are transmitted 
via NPY receptors and there are at least six subtypes of NPY receptors 
pharmacologically characterized up to date (for reviews, see Grundermar et 
al., 1993; Gehlert, 1994; Larhammar, 1996b). Recently four of them have 
been cloned and expressed 0-arhammar et al., 1992; Rose et al., 1995; 
Lundell et al., 1995; Weinberg et al., 1996). Analysis of the cDNA 
sequences deduces that NPY receptors may belong to the G-protein 
coupled-receptor family characterized by the putative structure with seven 
transmembrane domains. In InRlG9 cells, presence of NPY receptors 
have not been reported. However, since the cells responded to the 
neuropeptide, the presence of its receptor is implied. We also attempted 
to search for Y1 receptors on the InRlG9 cells using reverse-transcription 
polymerase chain reaction (RT-PCR). A pair of degenerate primers 
corresponding to the rat Y1 sequences which was designed in an earlier 
study (Lundell et al., 1995) was utilized in this experiment. Using various 
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annealing temperatures ranging from 37 ®C to 65 °C, in combination with 
varying concentrations 0fMgCl2, we were unable to obtain a signal for Y1 
receptor, while a band for tubulin of the expected size was obtained as a 
control. Our preliminary data suggest that Y1 receptor is probably absent 
on the M U G 9 cells and the observed effect o fNPY may be transduced by 
other subtypes of the receptor. Further studies are necessary to 
demonstrate the receptor subtype present on these cells when the cDNA 
sequences ofother subtypes ofthe NPY receptor family become available. 
Two second messenger systems have been proposed in the signal 
transduction o fNPY receptors. Ligand occupation of these receptors may 
result in a reduction of cAMP level but an elevation of intracellular Ca�+ 
concentrations _ c h e l , 1991; Grundemar et al., 1993). Jn this study, we 
investigated the effect offorskolin on proglucagon expression. Forskolin is 
an activator of adenylate cyclase resulting in an elevation of cAMP level. 
When forskolin was added to a final concentration of 10 '^ 10 : 10 "^  and 
10 -5 M in the presence of 11 mM glucose, an increasing trend of 
proglucagon mRNA accumulation was detected for the time points studied 
(1，4 and 16 hours oftreatment), mimicking the stimulatory action ofNPY. 
These results suggest that proglucagon gene expression may be stimulated 
by a cAMP-dependent pathway. In fact, the regulation of proglucagon 
gene expression by a cAMP-dependent pathway has been well 
documented (Drucker and Brubaker, 1989; Drucker et al, 1991; Lu et aI., 
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1996) and a cAMP-responsive element has been located in the 5，flanking 
region of glucagon gene (Knepel et al., 1990). Furthermore, it has been 
demonstrated that the cellular machinery required for this cAMP-response 
ofglucagon expression is fully functional in the M U G 9 cells (Matsumura 
et al., 1992; Miller et al., 1993; Gherzi et al., 1994). However, whether 
NPY acts through this pathway is still unclear from our results. One 
possibility is that NPY may stimulate proglucagon expression via 
pathways other than the cAMP-dependent pathway. It is also possible 
that unidentified G-protein coupling system of the NPY receptors is 
present, which activates adenylate cyclase to increase cAMP level and in 
tum stimulates glucagon gene expression. Hence, future experiments using 
agents that activate or inactivate adenylate cyclase together with NPY will 
be useful to elucidate the mechanism of action of NPY in stimulating 
glucagon gene expression in this cell line. Experiments measuring change in 
intracellular cAMP levels following NPY treatment may also provide 
useful information. 
Calcium is another second messenger involved in the signal 
transduction of NPY receptor and it has been found to be an important 
component of exocytosis. Therefore we examined the cellular calcium 
dynamics of the InRlG9 cells in response to NPY. In the study, InRlG9 
cells were superfused with synthetic interstitial fluid {SJF) in the presence 
of 11 mM glucose. Of the cells studied, 50 - 60% exhibited spontaneous 
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calcium oscillation of varying amplitude, frequency and regularity. 
Removal of extracellular calcium abolished the spontaneous oscillation, 
which was immediately resumed in Ca^^-containing Sff , suggesting that 
spontaneous calcium oscillation in these cells is dependent on Ca�+ influx 
from external source. Furthermore, the influx may possibly be transduced 
via voltage-dependent Ca�+ channels since an elevation of cytosolic Ca�+ 
was resulted when the cells were exposed to 40 mM ofKCl. Treatment 
with 3 ^iM co-conotoxin, an N-type calcium channel blocker, reduced the 
stimulated Ca�+ increase by KC1 and the effect of co-conotoxin was long-
lasting as the subsequent responses to KC1 were suppressed even after 
removal of the chemical. However it remains unclear from the result 
whether this type of channel is present in these cells. Thapsigargin is a 
known inhibitor ofintracellular calcium pump and at a concentration of 0.1 
^M, it induced a rise of cytosolic Ca�+ in both non-oscillating and 
spontaneously oscillating InRlG9 cells. In the latter, oscillation was 
2+ 
abolished after thapsigargin challenge, suggesting the involvement of Ca 
release from internal stores. These observations were highly consistent 
with a previous report on the characteristics of calcium oscillation in 
InRlG9 cells (Bode et al., 1994). In that study, 20 - 70% of InRlG9 cells 
exhibited spontaneous Ca�+ oscillation, which was abolished in the absence 
of external Ca�+. The responses to membrane depolarization and 
thapsigargin were also similar to those obtained in our study. 
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Furthermore, it was shown that the spontaneous calcium oscillation was 
not affected by 20 ^iM verapamil or 5 ^lM nifedipine, which are specific 
blockers ofL-type calcium channels, implying the absence o f th i s type of 
channels. 
In the present study, administration of 1 ^iM NPY in the presence 
of 11 mM glucose induced calcium oscillation in non-oscillating cells. In 
spontaneously oscillating cells, addition of NPY increased the frequency 
and amplitude ofcalcium oscillation. These results demonstrate that NPY 
acts directly on this cell line to elevate intracellular calcium level, which 
may trigger cellular responses such as Ca^^-regulated exocytosis. 
However, the NPY stimulated elevation of cytosolic Ca�+ was reduced 
when external Ca�+ was removed, suggesting that Ca�+ influx is involved in 
the NPY action. The NPY-induced calcium oscillations were not 
significantly different in the presence or absence of 5 [iM nifedipine, 
suggesting that the calcium influx caused by NPY is probably not via the 
L-type voltage-dependent calcium channel and these results are consistent 
with those reported previously OBode et al., 1994). In addition, since 
removal of external calcium reduced but not abolished the response to 
NPY，it is apparent that calcium from intracellular stores may contribute 
to the NPY-induced increase in cellular calcium level. Therefore, the cells 
were treated with 0.1 ^M ofthapsigargin to deplete the internal calcium 
stores. A spike ofincrease was observed in almost all cells studied. After 
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thapsigargin pretreatment, the NPY-induced calcium oscillation was 
substantially reduced, suggesting that calcium release from internal stores 
is also implicated. Taken together, NPY acts directly on the InRlG9 cells 
to elevate the cytosolic Ca�+ level, which is resulted from calcium influx 
from external source and calcium release from internal stores. Specificity 
ofaction o f N P Y was examined by treatment of InRlG9 cells with PYY. 
Our data showed that PYY at a final concentration of 1 ^iM was of no 
effect on calcium oscillation, while NPY at the same concentration 
stimulated a substantial rise in cytosolic calcium in the same cells studied. 
The lack ofeffect ofPYY on proglucagon gene expression and intracellular 
Ca2+ level suggests that the action o f N P Y is specific and it may play a 
modulatory role in glucagon synthesis and secretion. 
The involvement of calcium as a messenger in the regulation of 
insulin synthesis and secretion in pancreatic B cells has been well 
established. The activation ofinsulin secretion by glucose (Valdeolmillos et 
aL，1989) and the incretin hormones, GJP and GLP-l-(7-36) amide (Lu et 
al., 1993; Yada et al., 1993), are all transduced by enhanced mobilization of 
intracellular Ca�+. Regulation of glucagon secretion via changes of 
intracellular Ca�+ level in A cells has also been reported. For instance, 
spontaneous calcium oscillation was shown in isolated A cells (Berts et al., 
1995). Besides, while intracellular calcium level was potentiated by 
arginine, calcium oscillation was suppressed by glucose and insulin in A 
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cells (Wang and McDaniel, 1990; Berts et al., 1996). In the present study, 
our data showed that calcium oscillation was augmented in response to 1 
| iM NPY in the InRlG9 cells. One of the consequences of elevated 
intracellular free calcium may be the activation of calcium-regulated 
exocytosis (for review, see Schlegel and Mollard, 1995). Thus it is 
plausible to suggest that NPY may stimulate glucagon release via calcium-
regulated exocytosis. To clarify the role o f N P Y on glucagon release，we 
may measure the secretory level of glucagon in the culture medium by 
radioimmunoassay. 
Another possible role of calcium in signal transduction may be the 
stimulation of gene transcription. Elevation of cytosolic free calcium 
activates the Ca^^-calmodulin-dependent protein kinases (CaM kinases) I 
and II, which phosphorylate the same substrate as the cAMP-dependent 
protein kinase A (PKA) (Sheng et al., 1991; Pestell and Jameson, 1995 for 
review). The common substrate for CaM kinases and PKA is the cAMP-
response element-binding protein (CREB). CREB binds to the CRE in the 
promoter sequence of a gene to activate gene transcription. Hence, the 
CREB functions to converge the two important Ca�+ and cAMP signaling 
pathways and thus the highly coordinated regulation of gene transcription 
in response to multiple regulators or modulators can be ascertained. In 
islet cells, both glucagon and insulin genes have been found to possess the 
consensus CRE in their promoter sequences (Philippe, 1991). Evidence of 
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activation of transcription of glucagon and insulin by calcium is also 
available. For instance, glucagon gene transcription was stimulated by 
membrane depolarization by high potassium, which was attenuated in the 
presence of calcium channel blockers and calmodulin antagonists 
(Schwaninger et al , 1993). Likewise, transcription of insulin was also 
transduced via this pathway CEckert et aI, 1996). However, it is 
noteworthy that the former study also reported a non-responsiveness of 
glucagon gene transcription to membrane depolarization in InRlG9 cells 
under their experimental conditions. Our results showed that NPY 
stimulated both cytosolic calcium level and proglucagon gene expression in 
the M U G 9 cells. It is still possible that NPY activates the gene 
expression of glucagon via this calciumy'CaM kinases signaling pathway. 
However further investigations on the effect of membrane depolarization 
on glucagon gene expression in this cell line under our experimental set up 
may be useful to establish this hypothesis. 
In the present study, the effect of NPY on proinsulin mRNA 
expression was examined using the Rin 1056A cell line. Using the same 
experimental protocol, cells were treated with NPY in the presence of 5 
mM and 11 mM glucose for 4，8 and 16 hours. For the time points 
studied, there was no significant change in mRNA levels of proinsulin at 
either ofthe glucose level. One of the plausible explanations is that NPY 
may suppress insulin secretion by inhibiting exocytosis ofinsulin granules. 
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However, as the presence o f N P Y receptors has not been reported in this 
cell line, interpretation of these results has to be cautious. 
In conclusion, our results suggest that NPY acts directly on the 
glucagon-producing islet cell line (InRlG9). Taken into consideration of 
the time course of its action, the immediate effect of NPY may be the 
activation of calcium-regulated exocytosis to promote glucagon secretion, 
while the prolonged effect may be the increase in accumulation of steady-
state proglucagon mRNA, resulting in a stimulated rate of biosynthesis of 
glucagon. Therefore, our findings further support the view that NPY may 
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